Cerebrospinal fluid biomarkers in Creutzfeldt-Jakob disease

被引:50
作者
Van Everbroeck, B [1 ]
Boons, J [1 ]
Cras, P [1 ]
机构
[1] Univ Instelling Antwerp, Dept Neurobiol, Neurobiol Lab, Born Bunge Fdn, B-2610 Antwerp, Belgium
关键词
prion disease; 14-3-3; protein; tau protein; amyloid-beta; variant CJD; sporadic CJD; differential diagnosis;
D O I
10.1016/j.clineuro.2004.12.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Creutzfeldt-Jakob disease (CJD) is a rare neurodegenerative disorder. Since the emergence of variant CID (vCJD) vigilance concerning the disease's incidence has increased and the interest in accurate in vivo diagnosis has augmented. So far, a large number of biomarkers has been investigated as aid in the differential diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) and vCJD. These include, among others, neuron-specific enolase (NSE), microtubuli associated protein Tau, S-100 beta, amyloid-beta (A beta(1-42)) and the 14-3-3 protein. Multiple studies have confirmed that CSF detection of 14-3-3 protein by Western blot was the best single biomarker for sCJD with an average sensitivity and specificity of 92%. Also, in genetic and iatrogenic CJD (iCJD) patients with an average disease duration of less than 1 year, 14-3-3 is the best differential biomarker. Unfortunately, the 14-3-3 protein has a lower sensitivity if the disease duration exceeds beyond I year in both sporadic CID and other CJD types (vCJD, and specific genetic or iatrogenic CJD types). (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:355 / 360
页数:6
相关论文
共 58 条
[1]   14-3-3-ALPHA AND 14-3-3-DELTA ARE THE PHOSPHORYLATED FORMS OF RAF-ACTIVATING 14-3-3-BETA AND 14-3-3-ZETA - IN-VIVO STOICHIOMETRIC PHOSPHORYLATION IN BRAIN AT A SER-PRO-GLU-LYS MOTIF [J].
AITKEN, A ;
HOWELL, S ;
JONES, D ;
MADRAZO, J ;
PATEL, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (11) :5706-5709
[2]   14-3-3 PROTEINS - A HIGHLY CONSERVED, WIDESPREAD FAMILY OF EUKARYOTIC PROTEINS [J].
AITKEN, A ;
COLLINGE, DB ;
VANHEUSDEN, BPH ;
ISOBE, T ;
ROSEBOOM, PH ;
ROSENFELD, G ;
SOLL, J .
TRENDS IN BIOCHEMICAL SCIENCES, 1992, 17 (12) :498-501
[3]   Deaths from variant Creutzfeldt-Jakob disease in the UK [J].
Andrews, NJ ;
Farrington, CP ;
Ward, HJT ;
Cousens, SN ;
Smith, PG ;
Molesworth, AM ;
Knight, RSG ;
Ironside, JW ;
Will, RG .
LANCET, 2003, 361 (9359) :751-752
[4]   14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease [J].
Beaudry, P ;
Cohen, P ;
Brandel, JP ;
Delasnerie-Lauprêtre, N ;
Richard, S ;
Launay, JM ;
Laplanche, JL .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (01) :40-46
[5]   Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets [J].
Bieschke, J ;
Giese, A ;
Schulz-Schaeffer, W ;
Zerr, I ;
Poser, S ;
Eigen, M ;
Kretzschmar, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5468-5473
[6]   HUMAN 14-3-3 PROTEIN - RADIOIMMUNOASSAY, TISSUE DISTRIBUTION, AND CEREBROSPINAL-FLUID LEVELS IN PATIENTS WITH NEUROLOGICAL DISORDERS [J].
BOSTON, PF ;
JACKSON, P ;
THOMPSON, RJ .
JOURNAL OF NEUROCHEMISTRY, 1982, 38 (05) :1475-1482
[7]  
BROWN P, 1985, European Journal of Epidemiology, V1, P42, DOI 10.1007/BF00162311
[8]   Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent [J].
Bruce, ME ;
Will, RG ;
Ironside, JW ;
McConnell, I ;
Drummond, D ;
Suttie, A ;
McCardle, L ;
Chree, A ;
Hope, J ;
Birkett, C ;
Cousens, S ;
Fraser, H ;
Bostock, CJ .
NATURE, 1997, 389 (6650) :498-501
[9]  
Chapman T, 2001, NEUROLOGY, V56, P986
[10]   Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD [J].
Collinge, J ;
Sidle, KCL ;
Meads, J ;
Ironside, J ;
Hill, AF .
NATURE, 1996, 383 (6602) :685-690